Splenin is a synthetic tripeptide (Lys-Glu-Asp, KED) classified as a Khavinson-class bioregulator peptide targeted at splenic and immune tissue, investigated for immunomodulatory and cytoprotective properties through proposed gene expression regulatory mechanisms in lymphoid and hematopoietic cell populations. Like other short Khavinson bioregulator peptides, splenin is proposed to modulate gene expression in target immune cells via epigenetic mechanisms, with published research on the class demonstrating that ultrashort peptides can influence differentiation of stem and progenitor cells and regulate gene activity in aging tissues.

immune restoration, blood cell production, splenic function support.

Research on Splenin primarily documents effects related to immune restoration and blood cell production and splenic function support. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

For Splenin, its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

1 provider in the directory currently offers Splenin.

This review examines proposed epigenetic mechanisms by which ultrashort peptides including Khavinson tissue-specific peptides such as splenin may exert neuroprotective effects through interactions with histone proteins, DNA regulatory elements, and non-coding RNAs, offering a hypothesis for peptide-based modulation of neuroinflammatory and neurodegenerative processes.